Autifony is currently recruiting a Junior Medicinal Chemist, the position will be based in our lab in Stevenage, for more information and to apply please visit lnkd.in/dCNYKqC #science #greatplacetowork #chemist

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders, please take a look at our website for more details. #BoehringerIngelheim #Autifony #CNS

Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator, please take a look at our website for more information autifony.com

Autifony announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing disorders please visit autifony.com/news-events/ for more information #schizophrenia #hearingdisorders #FirstinHuman #clinicaltrials

Barbara Domayne-Hayman joined us on Careers in Discovery to talk startups, careers and more. Barbara's experience across biotech (current roles at Autifony Therapeutics, The Francis Crick Institute, Cambridge Enterprise and LifeArc) make this a must-listen. Get it at anchor.fm/careers-in-dis…. Enjoy! #work

Autifony Therapeutics regains rights to clinical stage Kv3 programme autifony.com/autifony-thera…

Autifony Therapeutics and Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders autifony.com/autifony-thera…

Great to see this exciting new collaboration between Autifony Therapeutics and Boehringer Ingelheim announced!

We are currently recruiting for a Senior Electrophysiologist who will be based in Padova Italy, please apply by sending your CV and a covering letter to [email protected]

Autifony CEO Charles Large will be speaking at the a webinar ‘Fragile X syndrome – in pursuit of a cure’ World Fragile X Day, Thurs 22 July 2021. worldfragilexday.com/fragile-x-synd…

We are currently recruiting a JNR Medicinal Chemist and a Quality Systems Administrator, for a full job description of either role, please email [email protected]

Autifony CEO Charles Large will be speaking in the Pharmaceutical Pipeline session at this year’s SIRS conference in Florence, Italy (6 – 10th April), he will present new analysis of the effects of Autifony’s lead Kv3 modulator, AUT00206 on gamma electroencephalographic activity.

We are currently recruiting, please visit our website autifony.com for full details of all positions

Our #PhaseIb study for AUT00201 in Progressive Myoclonic #Epilepsy-7 (#EPM7) has begun! Promising results in a mouse model led to a double-blind study at the Hospital of the University of Pennsylvania. Grateful for FDA designation and orphan-drug status: autifony.com/autifony-thera…

Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders autifony.com/autifony-annou… #Autifony #biotech #innovation #drugdiscovery

“Charles Large, Autifony CEO, talks to BiotechTV’s Amy Brown about progress in ion channel drug discovery and exciting hopes for novel treatments for rare paediatric epilepsy disorders.” player.vimeo.com/video/985909343

New news item on the Autifony website! autifony.com/progress-in-bo…

Charles Large,Autifony Therapeutics CEO, speaks at the 8th Sachs Neuroscience Innovation Forum in San Francisco (January 2025). #Autifony #ionchannel #biomakers #DrugDiscovery youtube.com/watch?v=wB40yG…

Our new website is now live #excitingtimes

We have a very exciting announcement today!